[
    [
        {
            "time": "",
            "original_text": "病毒无情 人间有爱 长春高新捐款500万助力抗击疫| 抗击疫情 上市公司在行动",
            "features": {
                "keywords": [
                    "长春高新",
                    "捐款",
                    "抗击疫情"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "病毒无情 人间有爱 长春高新捐款500万助力抗击疫| 抗击疫情 上市公司在行动",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "丽珠集团：丽珠微球平台国内第一，品种集中进入临床，研发进度加速【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "丽珠集团",
                    "微球平台",
                    "研发进度",
                    "临床"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "丽珠集团：丽珠微球平台国内第一，品种集中进入临床，研发进度加速【国盛医药张金洋团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "长春高新1季报点评：业绩高增长符合预期，生长激素业务展现韧性【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "长春高新",
                    "1季报",
                    "业绩高增长",
                    "生长激素"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新1季报点评：业绩高增长符合预期，生长激素业务展现韧性【国盛医药张金洋团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]